Weekly paclitaxel/ docetaxel combined with a platinum in the treatment of advanced non-small cell lung cancer: A study on efficacy, safety and pre-medication

Asian Pacific Journal of Cancer Prevention

Volumn 10, Issue 6, 2009, Pages 1147-1150

  Zhou, Jian Nong ^a   Huang, Xin En ^b   Ye, Zhuo ^c   Li, Chao ^b,d   Zhang, Qian ^b,d   Lin, Yong ^c   Jiang, Wei ^b   Sun, Wei Li ^b   Shi, Mei Qi ^b   Shu, Yong Qian ^a  

^a People's Hospital of Jiangsu   (China)

^b JIANGSU CANCER HOSPITAL   (China)

^c SOUTHEAST UNIVERSITY   (China)

^d NANJING MEDICAL UNIVERSITY   (China)

Author keywords

China; Docetaxel; Non small cell lung cancer; Paclitaxel; Platinum chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; OXALIPLATIN; PACLITAXEL; PLATINUM COMPLEX; TAXOID;

ADULT; AGED; ARTICLE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; METHODOLOGY; MIDDLE AGED; PREMEDICATION; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PACLITAXEL; PREMEDICATION; TAXOIDS; TREATMENT OUTCOME;

EID: 77956632517     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Akerley W, Herndon JE, Egorin MJ, et al (2003). Weekly, highdose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B. Cancer, 97, 2480-6.
2. Belotti D, Vergani V, Drudis T, et al (1996). Themicrotubuleaffecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res, 2, 1843-9.
3. Briasoulis E, Karavasilis V, Anastasopoulos D, et al (1999). Weekly docetaxel in minimally pretreated cancer patients: a dose-escalation study focused on feasibility and cumulative toxicity of long-term administration. Ann Oncol, 10, 701-6.
4. Camps C, Massuti B, Jimenez A, et al (2006). Randomized phase IIIstudy of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Ann Oncol, 17, 467-72.
5. Chang AY, Rubins J, Asbury R, et al (2001). Weekly paclitaxel in advanced non-small cell lung cancer. Semin Oncol, 28, 10-3.
6. Chen CH, Chang J W, Lee CH, et al (2005). Dose-finding and phase 2 study of weekly paclitaxel (Taxol) and cisplatin combination in treating Chinese patients with advanced nonsmall cell lung cancer. Am J Clin Oncol, 28, 508-12.
7. Fennelly D, Aghajanian C, Shapiro F, et al (1997). Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol, 15, 187-92.
8. Ferlay J, Bray F, Pisani P, et al (2001). GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0. IARC Cancer Base No 5. Lyon: IARC Press
9. Greco FA (1999). Docetaxel (Taxotere) administrated in weekly schedules. Semin Oncol, 26, 28-31.
10. Hainsworth JD, Burris HA 3rd, Erland JB, et al (1998). Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. Clin Oncol, 16, 2164-8.
11. Jatoi A, Stella PJ, Hillman S, et al (2003). Weekly carboplatin and paclitaxel in elderly non-small-cell lung cancer patients (ε65 years of age): a phase II North Central Cancer Treatment Group study. Am J Clin Oncol, 26, 441-7.
12. Jordan MA, Wendell K, Gardiner S, et al (1996). Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res, 56, 816-25.
13. Kaira K, Takise A, Minato K, et al (2005). Phase II study of weekly docetaxel and cisplatin in patients with non-small cell lung cancer. Anticancer Drugs, 16, 455-60.
14. Kaplan B, Altynbas M, Eroglu C, et al (2004). Preliminary results of a phase II study of weekly paclitaxel (PTX) and carboplatin (CBDCA)administered concurrently with thoracic radiation therapy (TRT) followed by consolidation chemotherapy with PTX/CBDCA for stage III unresectable non-small-cell lung cancer (NSCLC). Am J Clin Oncol, 27, 603-10.
15. Miller AB, Hoogstraten B, Staquet M, et al (1981). Reporting results of cancer treatment. Cancer, 47, 207-14.
16. Non-Small Cell Lung Cancer Collaborative Group (1995). Chemotherapy in non-small cell lung cancer. A meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ, 311, 899-909.
17. Rui MA, San B (2005). A clinical study on pacitaxel plus cisplatin combined therapy in the treatment of advanced non-small cell lung cancer. Chinese Clin Oncol, 10, 128-9.
18. Schiff PB, Fant J, Horwitz SB (2002). Promotion of microtubule assembly in vitro by taxol. Nature, 277, 665-7.
19. Schiller JH, Harrington D, Belani CP, et al (2002). Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med, 346, 92-8.
20. Seidman AD, Hudis CA, Albanel J, et al (1998). Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol, 16, 3353-61.
21. Tsunoda T, Koizumi T, Hayasaka M, et al (2004). Phase II study of weekly docetaxel combined with cisplatin in patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol, 54, 173-7.